Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results

se and milestone revenue

,000  Collaboration services revenue

4,0882,69511,6186,745Total revenue

79,088102,695136,618106,745Operating expenses*:  Research and Development

45,06619,072126,15050,285  Less: Excess amounts related to Research and Development

(34,146)-(51,523)-Research and Development, net

10,92019,07274,62750,285  General and Administrative

26,1204,86863,88213,149  Less: Excess amounts related to General and Administrative

(11,378)-(14,384)-General and Administrative, net

14,7424,86849,49813,149Total operating expenses

25,66223,940124,12563,434Income from operations

53,42678,75512,49343,311Interest and other income, net

14852204155Income before income taxes

53,57478,80712,69743,466Income tax provision (benefit)

11,2413,2019,924(2,411)Net income

45,877Net income per share:Basic


.62Weighted average shares used to computenet income per share:Basic


77,65974,45676,68473,840* Includes share-based compensation as follows:Research and development

,298General and administrative


 Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)(unaudited; in thousands, except per share data)Three Months EndedNine Months EndedSep. 30,Sep. 30,Sep. 30,Sep. 30,2013201220132012GAAP net income$ 42,333$ 75,606$   2,773$ 45,877Adjustments:Research and Development share-based compensation (2)

5,2872,59020,2276,298General and Administrative share-based compensation (2)

4,84957620,3482,20110,1363,16640,5758,499Non-GAAP net income$ 52,469$ 78,772$ 4

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
(Date:10/19/2014)... Shire plc (LSE: SHP, NASDAQ: ... Officer (CFO), has notified the Board of Directors of his decision ... career opportunity as CFO of Severn Trent plc.  James will leave ... commence a search for a new CFO immediately. Flemming ... build and lead a high-quality finance team at Shire. We are ...
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... healthcare landscape, the Medical Affairs function has come ... metrics, allocating resources efficiently and managing globalization.  ... at Best Practices, LLC is dedicated to providing ... issues. The Medical Affairs Consortium is a service ...
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Aliso Viejo, California (PRWEB) October 20, 2014 ... have announced the release of the Citrus theme for ... words I would use to describe the Citrus theme” Says ... been so easy to look so professional.” , Citrus comes ... . Included with the template are: four transitions for added ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... learned that you were at high risk of cancer because ... your children? A recent study at Fox Chase Cancer Center ... the next level and studied the parent perceptions of the ... be presented at the 2009 Annual Meeting of the American ...
... Chase Cancer Center uncovered a genetic pattern that may ... to the targeted therapy imatinib mesylate (Gleevec). Moreover, ... in order to make these tumors respond more readily ... in the laboratory of Andrew K. Godwin, PhD, at ...
... new pharmaceutical products in the pipeline combined with new ... the rare disease community, a senior Food and Drug ... by the National Organization for Rare Disorders (NORD).The blockbuster ... director of the Center for Drug Evaluation and Research ...
... 14 Hanger Orthopedic Group Inc. (NYSE: ... in the S&P SmallCap 600 after the close of trading ... acquired by privately held TriNet Group, Inc. in a transaction ... and post any relevant updates on its website: ...
... MedServe, Inc., a private company, today announced that it ... Stericycle, Inc. (Nasdaq: SRCL ) for $185 ... Avista Capital Partners, Chrysalis Ventures and Murphree Venture Partners ... collection, transportation, treatment and disposal of medical waste, hazardous ...
... ImQuest Bio and Arisyn jointly presented important ... inhibitor of hepatitis C virus (HCV) replication, at the 13th ... presentation highlighted the ability of PG301029 to potently suppress the ... potential mechanism of antiviral action through the selection of a ...
Cached Medicine News:Health News:Should parents share the results of BRCA1/2 genetic testing with their children? 2Health News:Gene signature may predict patient response to therapy for gastrointestinal stromal tumors 2Health News:NORD Sponsors Rare Disease Summit 2Health News:Standard & Poor's Announces Changes to U.S. Index 2Health News:MedServe to be Acquired by Stericycle for $185 Million 2Health News:MedServe to be Acquired by Stericycle for $185 Million 3Health News:ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference 2
Claes Shielded Retinotomy Scissors, Vertical...
... DxSelect is intended for qualitatively detecting antibodies ... serum. The test is indicated for testing ... an aid in the presumptive laboratory diagnosis ... intended for self-testing, and this test is ...
... Indirect immunofluorescent antibody (IFA) test for ... IgG antibodies to St. Louis Encephalitis virus ... Equine Encephalitis virus (EEE), and California Encephalitis/La ... 8-well slides with fixed individual spots of ...
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
Medicine Products: